John C. Papadimitriou
University of Maryland, Baltimore
Network
Latest external collaboration on country level. Dive into details by clicking on the dots.
Publication
Featured researches published by John C. Papadimitriou.
American Journal of Transplantation | 2008
Kim Solez; Robert B. Colvin; Lorraine C. Racusen; Mark Haas; B. Sis; Michael Mengel; Philip F. Halloran; William M. Baldwin; Giovanni Banfi; A. B. Collins; F. Cosio; Daisa Silva Ribeiro David; Cinthia B. Drachenberg; G. Einecke; Agnes B. Fogo; Ian W. Gibson; Samy S. Iskandar; Edward S. Kraus; Evelyne Lerut; Roslyn B. Mannon; Michael J. Mihatsch; Brian J. Nankivell; Volker Nickeleit; John C. Papadimitriou; Parmjeet Randhawa; Heinz Regele; Karine Renaudin; Ian S.D. Roberts; Daniel Serón; R. N. Smith
The 9th Banff Conference on Allograft Pathology was held in La Coruna, Spain on June 23–29, 2007. A total of 235 pathologists, clinicians and scientists met to address unsolved issues in transplantation and adapt the Banff schema for renal allograft rejection in response to emerging data and technologies. The outcome of the consensus discussions on renal pathology is provided in this article. Major updates from the 2007 Banff Conference were: inclusion of peritubular capillaritis grading, C4d scoring, interpretation of C4d deposition without morphological evidence of active rejection, application of the Banff criteria to zero‐time and protocol biopsies and introduction of a new scoring for total interstitial inflammation (ti‐score). In addition, emerging research data led to the establishment of collaborative working groups addressing issues like isolated ‘v’ lesion and incorporation of omics‐technologies, paving the way for future combination of graft biopsy and molecular parameters within the Banff process.
American Journal of Transplantation | 2007
Kim Solez; Robert B. Colvin; Lorraine C. Racusen; B. Sis; Philip F. Halloran; Patricia E. Birk; Patricia Campbell; Marilia Cascalho; A. B. Collins; Anthony J. Demetris; Cinthia B. Drachenberg; Ian W. Gibson; Paul C. Grimm; Mark Haas; Evelyne Lerut; Helen Liapis; Roslyn B. Mannon; P. B. Marcus; Michael Mengel; Michael J. Mihatsch; Brian J. Nankivell; Volker Nickeleit; John C. Papadimitriou; Jeffrey L. Platt; Parmjeet Randhawa; Ian S. Roberts; L. Salinas-Madriga; Daniel R. Salomon; D. Serón; M. T. Sheaff
The 8th Banff Conference on Allograft Pathology was held in Edmonton, Canada, 15–21 July 2005. Major outcomes included the elimination of the non‐specific term ‘chronic allograft nephropathy’ (CAN) from the Banff classification for kidney allograft pathology, and the recognition of the entity of chronic antibody‐mediated rejection. Participation of B cells in allograft rejection and genomics markers of rejection were also major subjects addressed by the conference.
American Journal of Transplantation | 2010
B. Sis; Michael Mengel; Mark Haas; Robert B. Colvin; Philip F. Halloran; Lorraine C. Racusen; Kim Solez; William M. Baldwin; Erika R. Bracamonte; Verena Broecker; F. Cosio; Anthony J. Demetris; Cinthia B. Drachenberg; G. Einecke; James M. Gloor; Edward S. Kraus; C. Legendre; Helen Liapis; Roslyn B. Mannon; Brian J. Nankivell; Volker Nickeleit; John C. Papadimitriou; Parmjeet Randhawa; Heinz Regele; Karine Renaudin; E. R. Rodriguez; Daniel Serón; Surya V. Seshan; Manikkam Suthanthiran; Barbara A. Wasowska
The 10th Banff Conference on Allograft Pathology was held in Banff, Canada from August 9 to 14, 2009. A total of 263 transplant clinicians, pathologists, surgeons, immunologists and researchers discussed several aspects of solid organ transplants with a special focus on antibody mediated graft injury. The willingness of the Banff process to adapt continuously in response to new research and improve potential weaknesses, led to the implementation of six working groups on the following areas: isolated v‐lesion, fibrosis scoring, glomerular lesions, molecular pathology, polyomavirus nephropathy and quality assurance. Banff working groups will conduct multicenter trials to evaluate the clinical relevance, practical feasibility and reproducibility of potential changes to the Banff classification. There were also sessions on quality improvement in biopsy reading and utilization of virtual microscopy for maintaining competence in transplant biopsy interpretation. In addition, compelling molecular research data led to the discussion of incorporation of omics‐technologies and discovery of new tissue markers with the goal of combining histopathology and molecular parameters within the Banff working classification in the near future.
The Journal of Pediatrics | 1999
Karoly Horvath; John C. Papadimitriou; Anna Rabsztyn; Cinthia B. Drachenberg; J. Tyson Tildon
OBJECTIVES Our aim was to evaluate the structure and function of the upper gastrointestinal tract in a group of patients with autism who had gastrointestinal symptoms. STUDY DESIGN Thirty-six children (age: 5.7 +/- 2 years, mean +/- SD) with autistic disorder underwent upper gastrointestinal endoscopy with biopsies, intestinal and pancreatic enzyme analyses, and bacterial and fungal cultures. The most frequent gastrointestinal complaints were chronic diarrhea, gaseousness, and abdominal discomfort and distension. RESULTS Histologic examination in these 36 children revealed grade I or II reflux esophagitis in 25 (69.4%), chronic gastritis in 15, and chronic duodenitis in 24. The number of Paneths cells in the duodenal crypts was significantly elevated in autistic children compared with non-autistic control subjects. Low intestinal carbohydrate digestive enzyme activity was reported in 21 children (58.3%), although there was no abnormality found in pancreatic function. Seventy-five percent of the autistic children (27/36) had an increased pancreatico-biliary fluid output after intravenous secretin administration. Nineteen of the 21 patients with diarrhea had significantly higher fluid output than those without diarrhea. CONCLUSIONS Unrecognized gastrointestinal disorders, especially reflux esophagitis and disaccharide malabsorption, may contribute to the behavioral problems of the non-verbal autistic patients. The observed increase in pancreatico-biliary secretion after secretin infusion suggests an upregulation of secretin receptors in the pancreas and liver. Further studies are required to determine the possible association between the brain and gastrointestinal dysfunctions in children with autistic disorder.
Journal of The American Society of Nephrology | 2002
Emilio Ramos; Cinthia B. Drachenberg; John C. Papadimitriou; Omar Hamze; Jeffrey C. Fink; David K. Klassen; Rene C. Drachenberg; Anne M. Wiland; Ravinder K. Wali; Charles B. Cangro; Eugene J. Schweitzer; Stephen T. Bartlett; Matthew R. Weir
Polyoma virus (PV) can cause interstitial nephritis and lead to graft failure in renal transplant recipients. The clinical course of patients with polyoma virus nephritis (PVN) is not well understood, partially due to its relatively low incidence. This study is a retrospective analysis of our experience over 4 yr. The specific purpose is to outline the clinical course and outcome of patients with PVN and to study the relationship between immunosuppression and the disease process. Between June 1997 and March 2001, 67 patients with graft dysfunction were found to have biopsy-proven PVN. The diagnosis was made at a mean of 12.8 +/- 9.9 mo posttransplantation. The majority of patients were men (79%) with a mean age of 54 +/- 14 yr (range, 28 to 75). All patients received immunosuppression with a calcineurin inhibitor (tacrolimus in 89% of patients). All patients except two received mycophenolate mofetil and prednisone. After the diagnosis of PVN, maintenance immunosuppression was reduced in 52 patients and remained unchanged in 15 patients. After reduction of immunosuppression, eight patients (15.3%) developed acute rejection and six (11.5%) became negative for PV in biopsy and urine. After a mean observation period of 12.6 mo (mean of 26 mo posttransplantation), 16.4% of patients had lost their grafts (8 of 52 in the reduction group and 3 of 15 in the no change group). In comparison to a case-matched polyoma virus-negative control group, the PVN patients were older (P =.0004) and there was a predominance of men (P = 0.02). Kaplan-Meier analysis demonstrated that patients with PVN had reduced graft survival compared with negative controls (P =.0004). It is concluded that PVN is a serious hazard for renal transplant recipients and contributes directly to graft loss. Antiviral drugs are needed, as the reduction of immunosuppression alone may not significantly improve graft function in patients with already established PVN. Although multiple factors probably play a role in the development of PVN, judicious use of immunosuppressive agents is indicated to minimize the occurrence of this infection.
American Journal of Transplantation | 2004
Cinthia B. Drachenberg; John C. Papadimitriou; Hans H. Hirsch; Ravinder K. Wali; Clinton D. Crowder; Joseph M. Nogueira; Charles B. Cangro; Susan R. Mendley; Ayesa N. Mian; Emilio Ramos
Polyomavirus‐associated nephropathy (PVAN) is a significant cause of allograft loss. The diagnosis requires allograft biopsy, but the impact of the histological features on diagnosis and outcome has not been described. We studied the distribution and extent of PVAN in 90 patients. Viral cytopathic changes, tubular atrophy/fibrosis and inflammation were semi‐quantitatively scored and classified into histological patterns. The histological findings were correlated with viruria, viremia and graft survival. PVAN lesions were random, (multi‐)focal and affected both cortex and medulla. Areas with PVAN coexisted with areas of unaffected parenchyma. In 36.5% (15/41) of biopsies with multiple tissue cores, discordant findings with PVAN‐positive and ‐negative cores were observed. However, all patients with PVAN had decoy cells in urine as well as significant viruria and viremia (mean of 2.5 × 108 and 2.32 × 107 viral copies, respectively). Biopsies showing lesser degrees of renal scarring at the time of diagnosis were associated with, more likely, resolution of the infection, in response to decrease of immunosuppression (p = 0.001). More advanced tubulointerstitial atrophy, active inflammation and higher creatinine level at diagnosis correlated with worse graft outcome (p = 0.0002, 0.0001 and 0.0006). Due to the focal nature of PVAN, correlation of biopsy results with viruria and viremia are required for diagnosis.
Human Pathology | 1999
Cinthia B. Drachenberg; Christian O. Beskow; Charles B. Cangro; Patricia M. Bourquin; Aylin Simsir; Jeffrey C. Fink; Matthew R. Weir; David K. Klassen; Stephen T. Bartlett; John C. Papadimitriou
Human polyoma virus (PV) interstitial nephritis occurs in immunosuppressed patients after reactivation of latent virus in renal epithelium. Currently, there is neither general consensus about the incidence of clinically significant PV infection in renal transplants nor conclusive evidence determining its significance in the long-term graft outcome. We evaluated 601 renal transplant biopsy specimens (from 365 patients) by routine light microscopy and immunoperoxidase stains with antibody against SV40 (which cross reacts with PV). We also examined urine samples from 200 patients (100 obtained concurrently with a renal biopsy in patients presenting with acute graft dysfunction and 100 from patients with stable graft function). Electron microscopic evaluation was performed in 50 renal biopsy specimens and in 23% of all urine samples. PV was identified in 1.8% biopsy specimens (1.9% of patients). PV interstitial nephritis showed the typical viral cytopathic changes in tubular epithelial cells associated with marked tubular damage and a disproportionately mild degree of tubulitis. There was no difference in the incidence of PV in the urine of patients with acutely deteriorating versus stable renal function (18% and 19%, respectively); however, urines with large numbers of infected cells (> 10/cytospin) and inflammatory changes in the sediments corresponded invariably to patients with acute allograft dysfunction (8 of 8), and in most cases to biopsy specimens showing PV interstitial nephritis (7 of 8). Based on these findings, urine samples seem to be the most sensitive and cost-effective screening method for PV infection; only urine samples with inflamed sediments and abundant infected cells correlate with clinically significant disease. In these cases, examination of a renal biopsy is indicated. Immunohistochemical stains are useful to confirm the presence of PV but do not increase the sensitivity of diagnosis of PV if this is not already suspected on routine light microscopy. In our material, immunostains were helpful ruling out the presence of PV in a small number of biopsy specimens (2%) that showed markedly reactive tubular cells resembling PV infection. Most patients with PV interstitial nephritis responded to decreased immunosuppression; however, the decay in graft function (based on creatinine slopes) was significantly more rapid in these patients than in matched controls. Evidence of PV infection should be systematically sought in renal biopsy specimens and urine samples from renal allograft recipients.
Journal of Immunology | 2001
Dimitrios Mastellos; John C. Papadimitriou; Silvia Franchini; Panagiotis A. Tsonis; John D. Lambris
Components of innate immunity have recently been implicated in the regulation of developmental processes. Most strikingly, complement factors appear to be involved in limb regeneration in certain urodele species. Prompted by these observations and anticipating a conserved role of complement in mammalian regeneration, we have now investigated the involvement of complement component C5 in liver regeneration, using a murine model of CCl4-induced liver toxicity and mice genetically deficient in C5. C5-deficient mice showed severely defective liver regeneration and persistent parenchymal necrosis after exposure to CCl4. In addition, these mice showed a marked delay in the re-entry of hepatocytes into the cell cycle (S phase) and diminished mitotic activity, as demonstrated, respectively, by the absence of 5-bromo-2′-deoxyuridine incorporation in hepatocytes, and the rare occurrence of mitoses in the liver parenchyma. Reconstitution of C5-deficient mice with murine C5 or C5a significantly restored hepatocyte regeneration after toxic injury. Furthermore, blockade of the C5a receptor (C5aR) abrogated the ability of hepatocytes to proliferate in response to liver injury, providing a mechanism by which C5 exerts its function, and establishing a critical role for C5aR signaling in the early events leading to hepatocyte proliferation. These results support a novel role for C5 in liver regeneration and strongly implicate the complement system as an important immunoregulatory component of hepatic homeostasis.
Transplantation | 2007
Cinthia B. Drachenberg; Hans H. Hirsch; John C. Papadimitriou; Rainer Gosert; Ravinder K. Wali; R. Munivenkatappa; Joseph M. Nogueira; Charles B. Cangro; Abdolreza Haririan; Susan R. Mendley; Emilio Ramos
Background. JC virus (JCV) viruria is more common than BK virus (BKV) viruria in healthy individuals but in kidney transplants (KT), polyomavirus nephropathy (PVAN) is primarily caused by BKV. Few cases of PVAN have been attributed to JCV. Systematic studies on JCV replication in KT are lacking. Methods. Out of a cohort of KT patients screened with urine cytology, patients shedding decoy cells were studied (n=103). Molecular studies demonstrated BKV, JCV, or BKV+JCV shedding in 58 (56.3%), 28 (27.2%), and 17 (16.5%), respectively. Biopsy was performed when decoy cells persisted 2 months or serum creatinine increased >20%. Results. BKV viruria was strongly associated with BKV viremia (93%), PVAN (48%, P=0.01) and graft loss (P=0.03). Higher BKV viremia correlated with graft dysfunction (P=0.01), more advanced histological pattern of PVAN (P<0.0001), and more infected cells in biopsy (P=0.0001). BKV viremia of ≥10,000 copies/mL was significantly associated with histologically confirmed PVAN (P=0.0001). Reduction of immunosuppression lead to disappearance of decoy cells in patients shedding BK (>93%). JCV viruria, was more often asymptomatic (P=0.002) and affected older patients (P=0.02). JCV PVAN was less common (21.4%) and was characterized by sparse cytopathic changes but significant inflammation and fibrosis. JCV viremia was rare (14.2%), transient, and low (mean 2.0E+03/mL). After reduction of immunosuppression decoy cells persisted in >50% of patients with JCV (P=0.0001), but no graft loss occurred. During the period of the current study, the incidence of BKV-PVAN was 5.5% and the incidence of JCV-PVAN was 0.9%. Conclusions. The data point to significant differences of BKV and JCV biology regarding replication and disease in KT patients, with important implications for screening and management.
The Lancet | 1998
Ravinder K. Wali; Cinthia I. Drachenberg; John C. Papadimitriou; Susan Keay; Emilio Ramos
A 37-year-old African-American man with schizophrenia and bipolar disorder was admitted with psychotic symptoms after stopping his medications. Within 2 weeks of admission, his blood urea increased from 8 to 21 mmol/L and creatinine from 203 to 450 mol/L. 3 weeks later his serum sodium was 135 mmol/L, potassium 6·7 mmol/L, chloride 109 mmol/L, bicarbonate 13 mmol/L, urea 32 mmol/L, and creatinine 770 mol/L. Calculated creatinine clearance was 7 mL/min and he required haemodialysis. His blood pressure was 132/70 mm Hg, weight 77 kg, and height 162 cm. He had pharyngeal thrush, penile warts, and prominent jugular veins without peripheral oedema. His medications were olanzapine, haloperidol, sodium valproate, and lorazepam. Additional laboratory tests indicated a normal urinary sediment on microscopy, urinary protein 9·9 g/day with normal urine and serum immunoelectrophoresis. He had a mild normocytic, normochromic anaemia, with haemoglobin of 95 g/L, and a normal platelet count. Serum albumin was 14 g/L and total cholesterol 7·2 mmol/L. Tests for collagen diseases, vasculitic syndromes, or infection with hepatitis or herpes group viruses were negative, and complement levels were normal; these tests were repeated 6 weeks later and remained unchanged. HIV-1 antibodies were present on enzyme-linked immunosorbent assay and western blot. His CD4 lymphocyte count was 0·04 10/L and the CD8 count 0·42 10/L. Serum HIV-1 RNA by branched chain DNA assay was 906 000 copies per mL. An ultrasound examination was remarkable for 13·5 cm kidneys with increased echogenicity. A percutaneous kidney biopsy was done a week before the initiation of dialysis and showed changes typical of HIV-1associated nephropathy. On light microscopy a core of renal cortex had fourteen glomeruli, of which one glomerulus was globally sclerotic. The other glomeruli were normocellular but had significant tuft collapse, with more than 70% having epithelial pseudocrescents. The interstitium showed prominent microcystic tubular dilatation containing proteinaceous casts (figure, A). The vessels were unremarkable, and glomerular immunofluorescence staining was negative. Electron microscopy confirmed collapsing glomerulopathy without endocapillary hypercellularity, plus marked hypertrophy and hyperplasia of the podocytes leading to epithelial pseudocrescents. Endothelial cells contained tubuloreticular cytoplasmic inclusions. Triple antiretroviral therapy with stavudine 20 mg/day, lamivudine 50 mg/day, and nelfinavir 1250 mg twice daily was started 1 week before haemodialysis. After13 weeks of treatment and 12 weeks of haemodialysis three times per week, a 24-hour urine collection (3·5 L) contained 0·7 g protein and 10·6 mmol creatinine. 2 weeks later repeat 24hour urine tests were similar and dialysis was discontinued. A repeat percutaneous renal biopsy at that time showed 18